Literature DB >> 10644071

Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity.

J C Olivier1, L Fenart, R Chauvet, C Pariat, R Cecchelli, W Couet.   

Abstract

PURPOSE: To investigate the mechanism underlying the entry of the analgesic peptide dalargin into brain using biodegradable polybutylcyanoacrylate (PBCA) nanoparticles (NP) overcoated with polysorbate 80.
METHODS: The investigations were carried out with PBCA NP and with non biodegradable polystyrene (PS) NP (200 nm diameter). Dalargin adsorption was assessed by HPLC. Its entry into the CNS in mice was evaluated using the tail-flick procedure. Locomotor activity measurements were performed to compare NP toxicities. BBB permeabilization by PBCA NP was studied in vitro using a coculture of bovine brain capillary endothelial cells and rat astrocytes.
RESULTS: Dalargin loading was 11.7 microg/mg on PBCA NP and 16.5 microg/ mg on PS NP. Adding polysorbate 80 to NP led to a complete desorption. Nevertheless, dalargin associated with PBCA NP and polysorbate 80 induced a potent and prolonged analgesia, which could not be obtained using PS NP in place of PBCA NP. Locomotor activity dramatically decreased in mice dosed with PBCA NP, but not with PS NP. PBCA NP also caused occasional mortality. In vitro, PBCA NP (10 microg/ml) induced a permeabilization of the BBB model.
CONCLUSIONS: A non specific permeabilization of the BBB, probably related to the toxicity of the carrier, may account for the CNS penetration of dalargin associated with PBCA NP and polysorbate 80.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10644071     DOI: 10.1023/a:1018947208597

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  13 in total

1.  An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro.

Authors:  M P Dehouck; S Méresse; P Delorme; J C Fruchart; R Cecchelli
Journal:  J Neurochem       Date:  1990-05       Impact factor: 5.372

2.  Tail-flick test: II. The role of supraspinal systems and avoidance learning.

Authors:  T E King; R L Joynes; J W Grau
Journal:  Behav Neurosci       Date:  1997-08       Impact factor: 1.912

3.  Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties.

Authors:  P Couvreur; B Kante; M Roland; P Guiot; P Bauduin; P Speiser
Journal:  J Pharm Pharmacol       Date:  1979-05       Impact factor: 3.765

4.  Molecular sieving characteristics of the cultured endothelial monolayer.

Authors:  A Siflinger-Birnboim; P J Del Vecchio; J A Cooper; F A Blumenstock; J M Shepard; A B Malik
Journal:  J Cell Physiol       Date:  1987-07       Impact factor: 6.384

5.  Capillary electrophoresis monitoring of the competitive adsorption of albumin onto the orosomucoid-coated polyisobutylcyanoacrylate nanoparticles.

Authors:  J C Olivier; M Taverna; C Vauthier; P Couvreur; D Baylocq-Ferrier
Journal:  Electrophoresis       Date:  1994-02       Impact factor: 3.535

6.  Toxicity of polyalkylcyanoacrylate nanoparticles I: Free nanoparticles.

Authors:  B Kante; P Couvreur; G Dubois-Krack; C De Meester; P Guiot; M Roland; M Mercier; P Speiser
Journal:  J Pharm Sci       Date:  1982-07       Impact factor: 3.534

7.  Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles.

Authors:  R N Alyautdin; V E Petrov; K Langer; A Berthold; D A Kharkevich; J Kreuter
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

8.  In vitro model for the degradation of alkylcyanoacrylate nanoparticles.

Authors:  R H Müller; C Lherm; J Herbort; P Couvreur
Journal:  Biomaterials       Date:  1990-10       Impact factor: 12.479

9.  Brain drug delivery of small molecules using immunoliposomes.

Authors:  J Huwyler; D Wu; W M Pardridge
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

10.  Evaluation of liver toxicological effects induced by polyalkylcyanoacrylate nanoparticles.

Authors:  R Fernandez-Urrusuno; E Fattal; D Porquet; J Feger; P Couvreur
Journal:  Toxicol Appl Pharmacol       Date:  1995-02       Impact factor: 4.219

View more
  28 in total

1.  In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles.

Authors:  Paul R Lockman; Joanna Koziara; Karen E Roder; Jennifer Paulson; Thomas J Abbruscato; Russell J Mumper; David D Allen
Journal:  Pharm Res       Date:  2003-05       Impact factor: 4.200

2.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

Review 3.  Drug transport to brain with targeted nanoparticles.

Authors:  Jean-Christophe Olivier
Journal:  NeuroRx       Date:  2005-01

Review 4.  Nanocarriers' entry into the cell: relevance to drug delivery.

Authors:  Hervé Hillaireau; Patrick Couvreur
Journal:  Cell Mol Life Sci       Date:  2009-06-05       Impact factor: 9.261

5.  Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line.

Authors:  Niladri Chattopadhyay; Jason Zastre; Ho-Lun Wong; Xiao Yu Wu; Reina Bendayan
Journal:  Pharm Res       Date:  2008-05-31       Impact factor: 4.200

Review 6.  Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis.

Authors:  Hu Yang
Journal:  Pharm Res       Date:  2010-07-01       Impact factor: 4.200

Review 7.  Agile delivery of protein therapeutics to CNS.

Authors:  Xiang Yi; Devika S Manickam; Anna Brynskikh; Alexander V Kabanov
Journal:  J Control Release       Date:  2014-06-21       Impact factor: 9.776

8.  A relevant in vitro rat model for the evaluation of blood-brain barrier translocation of nanoparticles.

Authors:  E Garcia-Garcia; S Gil; K Andrieux; D Desmaële; V Nicolas; F Taran; D Georgin; J P Andreux; F Roux; P Couvreur
Journal:  Cell Mol Life Sci       Date:  2005-06       Impact factor: 9.261

9.  Nanoparticulate transport of oximes over an in vitro blood-brain barrier model.

Authors:  Sylvia Wagner; Jürgen Kufleitner; Anja Zensi; Miriam Dadparvar; Sascha Wien; Judith Bungert; Tikva Vogel; Franz Worek; Jörg Kreuter; Hagen von Briesen
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

Review 10.  Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect.

Authors:  Hari Krishna Sajja; Michael P East; Hui Mao; Y Andrew Wang; Shuming Nie; Lily Yang
Journal:  Curr Drug Discov Technol       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.